Issue Date: June 20, 2016
Lonza to make Bluebird Bio drugs
Lonza has agreed to manufacture future commercial supplies of two lentiviral-based gene therapies for Bluebird Bio, a developer of drugs for genetic diseases and T cell-based immunotherapies for cancer. The two companies already have a multiyear relationship for clinical-scale materials. Now Lonza will build a dedicated production suite at its facility near Houston. The 9,300 m2 site, set to be completed in 2017, is designed to produce viral vectors and virally-modified cell therapy products using single-use bioreactors.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society